Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer
Journal of Hepato-Biliary-Pancreatic Sciences · 2025
DOI: 10.1002/jhbp.12122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2025. Verfasst von Won-Gun Yun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Ministry of Science and ICT, South Korea, Korea Health Industry Development Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
With the evolving treatment paradigms for pancreatic cancer, there is an increasing need for reliable markers to evaluate the effectiveness of preoperative chemotherapy. Due to the limitations of current indicators, this study aimed to evaluate the prognostic value of metabolic response based on the changes in the maximum standardized uptake value (SUV max ) on fluorine‐18‐fluorodeoxyglucose positron emission tomography.
Methods
This study included 210 patients with pancreatic cancer who underwent post‐chemotherapy curative surgery between 2013 and 2022. Using maximally selected rank statistics for survival, the metabolic response was defined as follows: metabolic responder (%ΔSUV max >75%), metabolic stable disease (15%–75%), and metabolic non‐responder (≤15%).
Results
Among patients, 15.7%, 66.7%, and 11.6% were categorized into the metabolic responder, metabolic stable disease, and metabolic non‐responder groups. The metabolic responder group (83.0 months) had longer median overall survival than the metabolic stable disease (51.0 months, p = .013) and metabolic non‐responder (32.0 months, p = .002) groups. In addition, being metabolic responders (vs. non‐responders) was an independent predictor of low recurrence rates (hazard ratio [95% confidence interval]: 0.46 [0.23–0.91]; p = .026) and achieving pathologic complete response (odds ratio [95% confidence interval]: 13.39 [1.61–300.77]; p = .035).
Conclusions
Metabolic response during preoperative chemotherapy has predictive power for post‐resection prognosis and residual tumor status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea.
- Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
- Cancer Research Institute & Institute on Aging, Seoul National University, Seoul, Republic of Korea.
ORCID-Profile: Won-Gun Yun, Youngmin Han, Go-Won Choi, Hye-Sol Jung, Wooil Kwon, Jin-Young Jang
Förderung
- Ministry of Science and ICT, South Korea
- Korea Health Industry Development Institute
Zitieren
APA
Yun, W. G., Kim, T. Y., Park, S., Han, Y., Choi, G. W., Jung, H. S., Kwon, W., Park, J. S., Cheon, G. J., & Jang, J. Y. (2025). Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.12122
Vancouver
Yun WG, Kim TY, Park S, Han Y, Choi GW, Jung HS, et al. Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences. 2025. doi:10.1002/jhbp.12122
BibTeX
@article{Yun2025,
author = {Yun, Won-Gun and Kim, Tae Young and Park, Seulah and Han, Youngmin and Choi, Go-Won and Jung, Hye-Sol and Kwon, Wooil and Park, Joon Seong and Cheon, Gi Jeong and Jang, Jin-Young},
title = {Metabolic response during preoperative chemotherapy can predict prognosis in pancreatic cancer},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2025},
doi = {10.1002/jhbp.12122}
}
EUVIMED